Android app on Google Play

Cantor Fitzgerald Maintains a 'Hold' on Hologic (HOLX); Acquisition Overshadows Challenging Quarter

May 1, 2012 12:51 PM EDT Send to a Friend
Get Alerts HOLX Hot Sheet
Price: $24.90 -1.19%

Rating Summary:
    8 Buy, 18 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 4
Trade HOLX Now!
Join SI Premium – FREE
Cantor Fitzgerald maintains a 'Hold' on Hologic (NASDAQ: HOLX) price target raised from $18 to $20.

Analyst, Jeremy Feffer, said, "The Gen-Probe (Nasdaq: GPRO) acquisition is a bold move and should pay dividends in the long term, but near-term growth concerns (Breast Health, GYN Surgical) persist, while integration will take some time. Our price target goes to $20, but we would still await a better entry point."

"Our 2012 revenue and EPS estimates come down slightly (from $1.37 to $1.36) on the Adiana discontinuation, and our 2013 model will not incorporate Gen-Probe until the acquisition closes. We like the deal long-term, but we remain concerned about the growth constraints near-term, particularly in the Breast Health and GYN Surgical segments."

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $19.12 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Mergers and Acquisitions

Related Entities

Cantor Fitzgerald, Dividend

Add Your Comment